Patrick F. Williams

“I think it's a little bit of all of it you know at the end of the day the product has been on the market for a little over 10 years neuromodulation is clearly an area we describe it as the the next frontier in terms of medical device and medicine and so if you think about the number of patients that are out there…”

“I will review our second quarter 2026 financial performance in more detail and then discuss our updated full-year guidance. As Scott mentioned, beginning this quarter, results from our distribution agreement with Dixie Medical are being reported as discontinued operations.”

“Yeah, the only thing I would add to that, Mike, is we're starting to look a lot deeper into the patient pipeline in terms of analytics and tracking that differently with our commercial team, and we think about it as sort of the velocity of that patient, which we know has a long sales cycle, but better understanding…”

“And so at J.P. Morgan, earlier in January, we did do a pre-announcement around that health care conference. Sorry about that, Mike. But as normal, we did pre-announce our results, and we also gave some guidance out for 2026.”

“We had divested from one of our other product lines that we're distributing last year called Dixie. And so the way that we think about potential, maybe top end of the range, as you just stated, was a little bit of what Joel said.”